Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase II dose-confirmation study

被引：0
|
作者：
Twelves, Chris [1 ,2 ]
Nasim, Muhammad Y. [3 ]
Anthoney, Alan [1 ,2 ]
Savulsky, Claudio I. [4 ]
Yin, Shuxin [4 ]
Evans, T. R. Jeffry [3 ]
机构：
[1] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[2] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[3] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow G12 8QQ, Lanark, Scotland
[4] Eisai & Co Ltd, Glasgow G12 8QQ, Lanark, Scotland
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P3-13-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-13-04
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: An open-label, phase II dose-confirmation study
    Savulsky, C.
    Twelves, C.
    Anthoney, A.
    Yin, S.
    Evans, T. R. J.
    Oncology Research and Treatment, 2015, 38 : 253 - 253
  • [2] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Twelves, Chris
    Anthoney, Alan
    Savulsky, Claudio, I
    Guo, Matthew
    Reyderman, Larisa
    Cresti, Nicola
    Semiglazov, Vladimir
    Timcheva, Constanta
    Zubairi, Ishtiaq
    Morrison, Rosemary
    Plummer, Ruth
    Evans, T. R. Jeffry
    BRITISH JOURNAL OF CANCER, 2019, 120 (06) : 579 - 586
  • [3] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Chris Twelves
    Alan Anthoney
    Claudio I. Savulsky
    Matthew Guo
    Larisa Reyderman
    Nicola Cresti
    Vladimir Semiglazov
    Constanta Timcheva
    Ishtiaq Zubairi
    Rosemary Morrison
    Ruth Plummer
    T. R. Jeffry Evans
    British Journal of Cancer, 2019, 120 : 579 - 586
  • [4] Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
    Twelves, Chris
    Awada, Ahmad
    Cortes, Javier
    Yelle, Louise
    Velikova, Galina
    Olivo, Martin S.
    Song, James
    Dutcus, Corina E.
    Kaufman, Peter A.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2016, 10 : 77 - 84
  • [5] Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer
    Savulsky, C.
    Nasim, M.
    Plummer, R.
    Evans, J.
    Morrison, R.
    Anthoney, A.
    Haney, S.
    Madi, A.
    Johnston, C.
    Carter, D.
    Reydermann, L.
    Gopalakrishna, P.
    Wanders, J.
    Twelves, C.
    ONKOLOGIE, 2012, 35 : 153 - 154
  • [6] Open label phase II study of capecitabine in combination with irinotecan (XEPTO) in patients with metastatic colorectal Cancer (MCRC)
    Raafat, Jahangir
    Sadighi, S.
    Shahrasbi, A. A.
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 87
  • [7] Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Kaufman, Peter A.
    Awada, Ahmad
    Twelves, Chris
    Yelle, Louise
    Perez, Edith A.
    Velikova, Galina
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina E.
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 594 - U202
  • [8] Phase II Study of Capecitabine in Combination With Thalidomide in Patients With Metastatic Breast Cancer
    Burris, Howard A., III
    Jones, Suzanne F.
    Shipley, Dianna
    Meluch, Anthony A.
    Greco, F. Anthony
    Barton, John H.
    Yardley, Denise A.
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (04) : 408 - 412
  • [9] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [10] Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
    Siena, Salvatore
    Van Cutsem, Eric
    Li, Mingyu
    Jungnelius, Ulf
    Romano, Alfredo
    Beck, Robert
    Bencardino, Katia
    Elena Elez, Maria
    Prenen, Hans
    Sanchis, Mireia
    Sartore-Bianchi, Andrea
    Tejpar, Sabine
    Gandhi, Anita
    Shi, Tao
    Tabernero, Josep
    PLOS ONE, 2013, 8 (11):
12345